Context Therapeutics Inc.
CNTX
$0.8595
-$0.0134-1.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.70% | 15.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 76.49% | 28.27% | |||
| Operating Income | -76.49% | -28.27% | |||
| Income Before Tax | -92.85% | -36.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -92.85% | -36.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -92.85% | -36.93% | |||
| EBIT | -76.49% | -28.27% | |||
| EBITDA | -76.55% | -28.27% | |||
| EPS Basic | -92.72% | -17.89% | |||
| Normalized Basic EPS | -92.69% | -18.04% | |||
| EPS Diluted | -92.72% | 42.33% | |||
| Normalized Diluted EPS | -92.69% | -18.04% | |||
| Average Basic Shares Outstanding | 0.00% | 16.18% | |||
| Average Diluted Shares Outstanding | 0.00% | 16.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||